Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Declines By 22.1%

Aditxt, Inc. (NASDAQ:ADTXGet Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 165,300 shares, a decrease of 22.1% from the April 15th total of 212,300 shares. Based on an average daily trading volume, of 353,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 8.5% of the company’s stock are short sold.

Institutional Trading of Aditxt

A hedge fund recently bought a new stake in Aditxt stock. Armistice Capital LLC bought a new stake in shares of Aditxt, Inc. (NASDAQ:ADTXFree Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,000 shares of the company’s stock, valued at approximately $350,000. Armistice Capital LLC owned approximately 11.67% of Aditxt at the end of the most recent quarter. Hedge funds and other institutional investors own 15.54% of the company’s stock.

Aditxt Price Performance

Shares of ADTX traded down $0.01 on Monday, hitting $2.06. 20,487 shares of the stock traded hands, compared to its average volume of 302,916. Aditxt has a one year low of $1.95 and a one year high of $68.08. The business has a 50 day simple moving average of $2.92 and a 200 day simple moving average of $3.93.

Aditxt Company Profile

(Get Free Report)

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.

Featured Articles

Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with's FREE daily email newsletter.